NewAmsterdam Pharma Company N.V.
(NAMS)Financial Statements · SEC EDGAR XBRL
Revenue
$22.5M
-50.6%
Net Income
-$203.0M
+16.1%
EPS
$-1.72
+32.8%
Op. Income
-$225.7M
-28.0%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Revenues
Total Revenues
Operating Expenses & Income
Selling General & Admin
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Interest Income/Expense
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)